Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF

Charles B. Goodwin, Zhenyun Yang, Fuqin Yin, Menggang Yu, Rebecca Chan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Juvenile myelomonocytic leukemia is a lethal disease of children characterized by hypersensitivity of hematopoietic progenitors to granulocyte macrophage-colony stimulating factor. Mutations in PTPN11, the gene encoding the protein tyrosine phosphatase Shp2, are common in juvenile myelomonocytic leukemia and induce hyperactivation of the phosphoinositide- 3-kinase pathway. We found that genetic disruption of Pik3r1, the gene encoding the Class IA phosphoinositide-3-kinase regulatory subunits p85α, p55α and p50α, significantly reduced hyperproliferation and hyperphosphorylation of Akt in gainof- function Shp2 E76K-expressing cells. Elevated protein levels of the phosphoinositide-3-kinase catalytic subunit, p110δ, in the Shp2 E76K-expressing Pik3r1-/- cells suggest that p110δ may be a crucial mediator of mutant Shp2-induced phosphoinositide- 3-kinase hyperactivation. Consistently, treatment with the p110δ-specific inhibitor, IC87114, or the clinical grade pan-phosphoinositide-3-kinase inhibitor, GDC-0941, reduced granulocyte macrophage-colony stimulating factor hypersensitivity. Treatment with the farnesyltransferase inhibitor, tipifarnib, showed that Shp2 E76K induces hyperactivation of phosphoinositide-3-kinase by both Ras-dependent and Ras-independent mechanisms. Collectively, these findings implicate Class IA phosphoinositide-3-kinase as a relevant molecular target in juvenile myelomonocytic leukemia.

Original languageEnglish
Pages (from-to)1042-1047
Number of pages6
JournalHaematologica
Volume97
Issue number7
DOIs
StatePublished - Jul 1 2012

Fingerprint

1-Phosphatidylinositol 4-Kinase
Granulocyte-Macrophage Colony-Stimulating Factor
Phosphatidylinositol 3-Kinases
Hypersensitivity
Juvenile Myelomonocytic Leukemia
tipifarnib
Farnesyltranstransferase
Protein Tyrosine Phosphatases
Catalytic Domain
Proteins
Mutation
Therapeutics
Genes

Keywords

  • Granulocyte macropage colony stimulating factor
  • Juvenile myelomonocytic leukemia
  • Phosphoinositide 3-kinase
  • PTPN11

ASJC Scopus subject areas

  • Hematology

Cite this

Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. / Goodwin, Charles B.; Yang, Zhenyun; Yin, Fuqin; Yu, Menggang; Chan, Rebecca.

In: Haematologica, Vol. 97, No. 7, 01.07.2012, p. 1042-1047.

Research output: Contribution to journalArticle

Goodwin, Charles B. ; Yang, Zhenyun ; Yin, Fuqin ; Yu, Menggang ; Chan, Rebecca. / Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. In: Haematologica. 2012 ; Vol. 97, No. 7. pp. 1042-1047.
@article{3f16a4f565a04870a0cbf7b9a08c14ce,
title = "Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF",
abstract = "Juvenile myelomonocytic leukemia is a lethal disease of children characterized by hypersensitivity of hematopoietic progenitors to granulocyte macrophage-colony stimulating factor. Mutations in PTPN11, the gene encoding the protein tyrosine phosphatase Shp2, are common in juvenile myelomonocytic leukemia and induce hyperactivation of the phosphoinositide- 3-kinase pathway. We found that genetic disruption of Pik3r1, the gene encoding the Class IA phosphoinositide-3-kinase regulatory subunits p85α, p55α and p50α, significantly reduced hyperproliferation and hyperphosphorylation of Akt in gainof- function Shp2 E76K-expressing cells. Elevated protein levels of the phosphoinositide-3-kinase catalytic subunit, p110δ, in the Shp2 E76K-expressing Pik3r1-/- cells suggest that p110δ may be a crucial mediator of mutant Shp2-induced phosphoinositide- 3-kinase hyperactivation. Consistently, treatment with the p110δ-specific inhibitor, IC87114, or the clinical grade pan-phosphoinositide-3-kinase inhibitor, GDC-0941, reduced granulocyte macrophage-colony stimulating factor hypersensitivity. Treatment with the farnesyltransferase inhibitor, tipifarnib, showed that Shp2 E76K induces hyperactivation of phosphoinositide-3-kinase by both Ras-dependent and Ras-independent mechanisms. Collectively, these findings implicate Class IA phosphoinositide-3-kinase as a relevant molecular target in juvenile myelomonocytic leukemia.",
keywords = "Granulocyte macropage colony stimulating factor, Juvenile myelomonocytic leukemia, Phosphoinositide 3-kinase, PTPN11",
author = "Goodwin, {Charles B.} and Zhenyun Yang and Fuqin Yin and Menggang Yu and Rebecca Chan",
year = "2012",
month = "7",
day = "1",
doi = "10.3324/haematol.2011.046896",
language = "English",
volume = "97",
pages = "1042--1047",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",

}

TY - JOUR

T1 - Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF

AU - Goodwin, Charles B.

AU - Yang, Zhenyun

AU - Yin, Fuqin

AU - Yu, Menggang

AU - Chan, Rebecca

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Juvenile myelomonocytic leukemia is a lethal disease of children characterized by hypersensitivity of hematopoietic progenitors to granulocyte macrophage-colony stimulating factor. Mutations in PTPN11, the gene encoding the protein tyrosine phosphatase Shp2, are common in juvenile myelomonocytic leukemia and induce hyperactivation of the phosphoinositide- 3-kinase pathway. We found that genetic disruption of Pik3r1, the gene encoding the Class IA phosphoinositide-3-kinase regulatory subunits p85α, p55α and p50α, significantly reduced hyperproliferation and hyperphosphorylation of Akt in gainof- function Shp2 E76K-expressing cells. Elevated protein levels of the phosphoinositide-3-kinase catalytic subunit, p110δ, in the Shp2 E76K-expressing Pik3r1-/- cells suggest that p110δ may be a crucial mediator of mutant Shp2-induced phosphoinositide- 3-kinase hyperactivation. Consistently, treatment with the p110δ-specific inhibitor, IC87114, or the clinical grade pan-phosphoinositide-3-kinase inhibitor, GDC-0941, reduced granulocyte macrophage-colony stimulating factor hypersensitivity. Treatment with the farnesyltransferase inhibitor, tipifarnib, showed that Shp2 E76K induces hyperactivation of phosphoinositide-3-kinase by both Ras-dependent and Ras-independent mechanisms. Collectively, these findings implicate Class IA phosphoinositide-3-kinase as a relevant molecular target in juvenile myelomonocytic leukemia.

AB - Juvenile myelomonocytic leukemia is a lethal disease of children characterized by hypersensitivity of hematopoietic progenitors to granulocyte macrophage-colony stimulating factor. Mutations in PTPN11, the gene encoding the protein tyrosine phosphatase Shp2, are common in juvenile myelomonocytic leukemia and induce hyperactivation of the phosphoinositide- 3-kinase pathway. We found that genetic disruption of Pik3r1, the gene encoding the Class IA phosphoinositide-3-kinase regulatory subunits p85α, p55α and p50α, significantly reduced hyperproliferation and hyperphosphorylation of Akt in gainof- function Shp2 E76K-expressing cells. Elevated protein levels of the phosphoinositide-3-kinase catalytic subunit, p110δ, in the Shp2 E76K-expressing Pik3r1-/- cells suggest that p110δ may be a crucial mediator of mutant Shp2-induced phosphoinositide- 3-kinase hyperactivation. Consistently, treatment with the p110δ-specific inhibitor, IC87114, or the clinical grade pan-phosphoinositide-3-kinase inhibitor, GDC-0941, reduced granulocyte macrophage-colony stimulating factor hypersensitivity. Treatment with the farnesyltransferase inhibitor, tipifarnib, showed that Shp2 E76K induces hyperactivation of phosphoinositide-3-kinase by both Ras-dependent and Ras-independent mechanisms. Collectively, these findings implicate Class IA phosphoinositide-3-kinase as a relevant molecular target in juvenile myelomonocytic leukemia.

KW - Granulocyte macropage colony stimulating factor

KW - Juvenile myelomonocytic leukemia

KW - Phosphoinositide 3-kinase

KW - PTPN11

UR - http://www.scopus.com/inward/record.url?scp=84863967243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863967243&partnerID=8YFLogxK

U2 - 10.3324/haematol.2011.046896

DO - 10.3324/haematol.2011.046896

M3 - Article

C2 - 22315502

AN - SCOPUS:84863967243

VL - 97

SP - 1042

EP - 1047

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 7

ER -